{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:43:50Z","timestamp":1793497430300,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jaad.2024.09.027","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T23:04:30Z","timestamp":1733007870000},"page":"S27-S30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"S","title":["Biologics in hidradenitis suppurativa: Progress and new directions"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3784-7091","authenticated-orcid":false,"given":"Alexandra","family":"Charrow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Santiago-Soltero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2024.09.027_bib2","series-title":"StatPearls","article-title":"Adalimumab","author":"Ellis","year":"2024"},{"issue":"10378","key":"10.1016\/j.jaad.2024.09.027_bib3","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"issue":"10443","key":"10.1016\/j.jaad.2024.09.027_bib4","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jaad.2024.09.027_bib6","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/jdv.15163","article-title":"Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa","volume":"32","author":"Kimball","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2024.09.027_bib7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2024.09.027_bib8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamadermatol.2021.4805","article-title":"Drug survival of biologics in patients with hidradenitis suppurativa","volume":"158","author":"Ring","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.09.027_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjd.19863","article-title":"Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study","volume":"185","author":"Prens","year":"2021","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.09.027_bib10","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1097\/MIB.0000000000000359","article-title":"Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease","volume":"21","author":"Bouguen","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1016\/j.jaad.2024.09.027_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15691","article-title":"Infliximab in hidradenitis suppurativa: a systematic review and meta-analysis","volume":"35","author":"Shih","year":"2022","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jaad.2024.09.027_bib12","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jaad.2019.09.071","article-title":"High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa","volume":"82","author":"Ghias","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.09.027_bib13","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jaad.2019.05.022","article-title":"Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa","volume":"81","author":"Oskardmay","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.09.027_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14494","article-title":"Certolizumab pegol for hidradenitis suppurativa: Case report and literature review","volume":"33","author":"Holm","year":"2020","journal-title":"Dermatol Ther"},{"issue":"11","key":"10.1016\/j.jaad.2024.09.027_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15782","article-title":"Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: a real-life experience","volume":"35","author":"Esme","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2024.09.027_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/20406223241257342","article-title":"Golimumab and certolizumab pegol for the treatment of hidradenitis suppurativa: a literature review and future perspective","volume":"15","author":"Heidari","year":"2024","journal-title":"Ther Adv Chronic Dis"},{"issue":"3","key":"10.1016\/j.jaad.2024.09.027_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15266","article-title":"Golimumab, as an alternative treatment in patients with coexisting hidradenitis suppurativa and arthritis after adalimumab failure: report of two cases","volume":"35","author":"Ramos","year":"2022","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.jaad.2024.09.027_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/bjd\/ljad225","article-title":"The interleukin-1 pathway as a treatment target in early-stage hidradenitis suppurativa?","volume":"189","author":"Suhrkamp","year":"2023","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.09.027_bib20","doi-asserted-by":"crossref","DOI":"10.25251\/skin.7.supp.286","article-title":"Spesolimab for hidradenitis suppurativa: a proof-of-concept study","volume":"7","author":"Alavi","year":"2023","journal-title":"J Skin"},{"issue":"3","key":"10.1016\/j.jaad.2024.09.027_bib21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40257-024-00860-5","article-title":"American academy of dermatology annual meeting: San Diego, CA, USA, 8-12 March 2024","volume":"25","author":"Fraser","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.09.027_bib22","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s13555-023-00913-3","article-title":"Efficacy and safety of risankizumab for the treatment of hidradenitis suppurativa: a phase 2, randomized, placebo-controlled trial","volume":"13","author":"Kimball","year":"2023","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jaad.2024.09.027_bib23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40257-019-00439-5","article-title":"Biologic treatment for hidradenitis suppurativa","volume":"20","author":"Flood","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.09.027_bib24","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40257-024-00880-1","article-title":"Hidradenitis suppurativa: new targets and emerging treatments","volume":"25","author":"Gao","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2024.09.027_bib25","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.2147\/CCID.S301794","article-title":"Obstacles to early diagnosis and treatment of hidradenitis suppurativa: current perspectives on improving clinical management","volume":"16","author":"Snyder","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.09.027_bib26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/FTD.0000000000001095","article-title":"Challenges in therapeutic drug monitoring: optimizing biological treatments in patients with inflammatory bowel disease and other immune-mediated inflammatory diseases","volume":"45","author":"Papamichael","year":"2023","journal-title":"Ther Drug Monit"},{"issue":"10","key":"10.1016\/j.jaad.2024.09.027_bib27","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/ibd\/izac259","article-title":"Influence of HLADQA1\u221705 genotype in adults with inflammatory bowel disease and anti-TNF treatment with proactive therapeutic drug monitoring: a retrospective cohort study","volume":"29","author":"Fuentes-Valenzuela","year":"2023","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1016\/j.jaad.2024.09.027_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12093271","article-title":"Anti-drug antibodies in the biological therapy of autoimmune rheumatic diseases","volume":"12","author":"Pizano-Martinez","year":"2023","journal-title":"J Clin Med"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224028809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224028809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T21:11:12Z","timestamp":1733865072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224028809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0190962224028809"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.09.027","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics in hidradenitis suppurativa: Progress and new directions","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}